Farnesyl transferase inhibition in hematologic malignancies

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue SUPPL. 1, 2005, Pages

  Karp, Judith E ^a,b  

^a Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ^*

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Carcinoma; Farnesyl transferase inhibition; Hematologic malignancies; Signal transduction

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; FARNESYL TRANS TRANSFERASE; IMATINIB; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SARASA; TIPIFARNIB; ANTINEOPLASTIC AGENT; QUINOLONE DERIVATIVE;

ACUTE LEUKEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG INHIBITION; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HUMAN; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROLOGIC DISEASE; SIGNAL TRANSDUCTION; SKIN DISEASE; TREATMENT RESPONSE; ARTICLE; BLOOD DISEASE; DRUG ANTAGONISM;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; FARNESYLTRANSTRANSFERASE; HEMATOLOGIC NEOPLASMS; HUMANS; QUINOLONES;

EID: 33644842130     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Lancet JE, Karp JE. Farnesyl transferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 2003;102:4512-4519.
2. Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma 2004; 45:2187-2195.
3. Cortes J. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma 2003;4(suppl 1):S30-S35.
4. Sebti SM, Der CJ. Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 2003;3: 945-951.
5. Beaupre DM, Cepero E, Obeng EA, et al. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther 2004;3:179-186.
6. Bruzek LM, Poynter JN, Kaufmann SH, Adjei AA. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)- cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1 -piperidinecarboxamide (SCH66336). Mol Pharmacol 2005;68:477-486.
7. Le Gouill S, Pellat-Deceunynck C, Harousseau JL, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002;16:1664-1667.
8. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97: 3361-3369.
9. Raponi M, Belly RT, Karp JE, et al. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 2004;4:56.
10. Lancet JE, Gotlib J, Gojo I, et al. Tipifarnib (Zarnestra) in previously untreated poor-risk AML of the elderly: Updated results of a multi-center phase 2 trial. Blood 2004; 104:249a.
11. Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 2005;4:77-84.
12. Kurzrock R, Albitar M, Cortes J, et al. Phase I study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004:22:1287-1292.
13. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndromes: Clinical and biologic activities in the phase 1 setting. Blood 2003; 102:4527-4534.
14. Feldman EJ. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 2005:4:186-190.
15. Cortes J. CMML: A biologically distinct myeloproliferative disease. Curr Hematol Rep 2003;2:202-208.
16. Cortes J, Albitar M, Thomas D, et al. Efficacy of farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101: 1692-1697.
17. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol 2003;40:79-86.
18. Mesa RA, Tefferi A, Gray LA, et al. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 2003;17: 849-855.
19. Cortes J, Garcia-Manero G, O'Brien S, et al. A Phase I study of Tipifarnib in combination with imatinib (IM) for patients with chronic myeloid leukemia in chronic phase who failed IM therapy. Blood 2004;104:289a.
20. Cortes J, O'Brien S, Verstovek S, et al. Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients with chronic myeloid leukemia after failure with imatinib. Blood 2004;104:288a.
21. Daley GQ. Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors. Semin Hematol 2003;40(suppl 2):11-14.
22. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004;103:3271-3277.